Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 15;8(11):20813-20.
eCollection 2015.

Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heart disease between diabetic and non-diabetic patients

Liming Lin  1 , Cheng Jin  2 , Xiaoming Wei  2 , Huiying Li  2 , Jihong Shi  2 , Shouling Wu  2 , Xiaojie Yang  3 , Xiangqian Qi  4
Affiliations

Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heart disease between diabetic and non-diabetic patients

Liming Lin et al. Int J Clin Exp Med. .

Abstract

Objective: The aim of this study is to examine and compare the efficacy of everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in coronary heart disease in diabetic or non-diabetic patients.

Methods: A total of 666 patients needed for percutaneous coronary intervention were randomly selected from June 2008 to June 2013 in our hospital and were divided into two groups: (i) coronary heart disease with diabetes group and (ii) non-diabetes group. Patients in each group were further assigned to receive treatment of either EES or ZES. Then we observed the major adverse cardiac events, including mortality, nonfatal myocardial infarction and non-fatal cerebrovascular events over the period of 15 months after initial stent implantation.

Results: Compared to the non-diabetic group, more patients in diabetic group had received anti-hypotensive treatment (72% vs. 49%, P < 0.0001) and hypolipemic treatment (80% vs. 67%, P < 0.0001) before the percutaneous coronary intervention. In both diabetic group and non-diabetic group, patients received ZES treatment had a much greater incidence rate of major adverse cardiac events compared to the patients received EES treatment (P < 0.05). Meanwhile, target lesion revascularization rate in the ZES group was also significantly higher than that in the EES group. The data showed big differences between ZES and EES groups with important statistical significance (P < 0.05).

Conclusion: Patients with coronary heart disease and diabetes have a higher risk of major adverse cardiac events after stent implantation. EES treatment is safer with higher efficacy in our study, being a more effective stent for the patients merged with diabetes.

Keywords: Everolimus-eluting stent; coronary heart disease; diabetes; zotarolimus-eluting stents.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier plots for adverse cardiac events over 15 Months of Follow-up, showing a big difference in the incidence of the adverse cardiac events between the ZES (solid line) and EES (dot line) group.
Figure 2
Figure 2
Kaplan-Meier plots show the unadjusted risk of all-cause mortality, showing a difference of mortality incidence between ZES (solid line) and EES (dot line) group.
Figure 3
Figure 3
Kaplan-Meier plots show the unadjusted risk of target lesion revascularization. Significant difference between ZES (solid line) and EES (dot line) groups were shown in incidence of target lesion revascularization over 15 months of follow-up.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Maeng M, Jensen LO, Kaltoft A, Hansen HH, Bøttcher M, Lassen JF, Thayssen P, Krusell LR, Rasmussen K, Pedersen L, Sørensen HT, Johnsen SP, Thuesen L. Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus. Am J Cardiol. 2008;102:165–172. - PubMed
    1. Pendyala LK, Loh JP, Kitabata H, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Pichard AD, Waksman R. The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era. J Interv Cardiol. 2014;27:391–398. - PubMed
    1. Raja SG, Benedetto U, Ilsley CD, Amrani M. Multiple arterial grafting confers survival advantage compared to percutaneous intervention with drug-eluting stents in multivessel coronary artery disease: A propensity score adjusted analysis. Int J Cardiol. 2015;189:153–158. - PubMed
    1. Tian W, Lhermusier T, Minha S, Waksman R. Rational use of rotational atherectomy in calcified lesions in the drug-eluting stent era: Review of the evidence and current practice. Cardiovasc Revasc Med. 2015;16:78–83. - PubMed
    1. Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco DJ, Dawkins KD. Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent: The EVOLVE II Randomized Trial. Circ Cardiovasc Interv. 2015;8:e002372. - PubMed

LinkOut - more resources